Developmental Core Description
The Developmental Core provides mentoring support for early stage investigators who are interested in pursuing an HIV research career. We work collaboratively with other CFAR Cores to identify scientific and career mentors as needed, upon request.
The UNC CFAR Developmental Core provides funding for Traditional Developmental Awards, Notices of Special Interest (NOSIs) including a Secondary Data Analysis NOSI and an HIV-COVID NOSI, and Microgrants to emerging HIV investigators for one year of research. Awards are made for/to one of the following:
-Early stage investigators*
-Experienced investigators new to HIV
A senior mentor is required to assist early stage Awardees in preparing the application, executing the project, preparing a manuscript, and writing a resulting larger grant proposal to the NIH. Research can be basic, translational, clinical, or social/behavioral, and can address treatment, transmission, or prevention. There are several opportunities during the year for Awardees to present their work.
*Early stage investigators are defined as never having served as a PI on an R01 or R01 equivalent grant; holding a terminal degree (e.g. Ph.D., MD); eligible to serve as PI on NIH grant; and employed at UNC, FHI 360, RTI, or a NC HBCU.
The CFAR Developmental Cohort is open to Early Stage Investigators affiliated with the CFAR. The Dev Cohort leverages a wide range of professional development resources, and provides opportunities for its members to receive structured feedback from CFAR leadership on their research. Dev Cohort meetings are held monthly throughout the school year, currently virtually. Each year’s Cohort will participate in grant-writing and manuscript-writing workshops, receive personalized feedback on Specific Aims from each other and established investigators, and be given the opportunity to attend a Q&A session with researchers who serve on NIH review panels. Additional meeting topics are driven by members’ interests and may include partnering with the UNC Health Sciences Library to present seminars on topics such as effective poster design, impact measurement and visualization, and/or choosing where to publish; a nationally-recognized Burnout Prevention Program presented by the UNC Department of Psychiatry; and/or sensitivity training for working with the transgender community.
Developmental Core News
More 2020 Developmental Awardees
Congratulations to the 2020 Developmental Awardees!
Abigail Hatcher, Towards a therapeutic intervention for pregnant adolescents living with HIV and partner violence
Lauren Hill, Developing an Online PrEP Shared Decision-Making Aid for US Women
Sarah Rutstein, Genomics of Genital Ulcer Disease of Unknown Etiology Among Persons with HIV or at High Risk for HIV-infection in Malawi
Meet one of the women from UNC working to develop a COVID-19 vaccine
UNC-CH is one of 89 testing sites for Moderna’s phase 3 clinical trial for a COVID-19 vaccine. Read more from this WRAL article featuring Dr. Cindy Gay, a former Developmental awardee, who is leading the phase 3 clinical trial UNC site.
COVID-19 Mental Health and Emotional Support Resources
We appreciate all that CFAR members are doing to help during the COVID-19 pandemic. Please remember to take care of yourselves in these challenging times. Our own Dr. Samantha Meltzer-Brody and her colleagues have put together a list of mental health and emotional support resources that we encourage you to utilize.
2020 Developmental Awardees
Congratulations to the 2020 Developmental Awardees!
Guochun Jiang, HIV reservoirs in the central nervous system
Tips on choosing a mentor from NIH: https://www.niaid.nih.gov/grants-contracts/tips-choosing-mentor
NIAID guidance for writing a grant application can also be found on-line.
If you are conducting NIH-funded research that involves human subjects, or are considering applying to NIH for support of such research, we want to call your attention to important changes that may affect how you: • select the right NIH funding opportunity announcement First, familiarize yourself with the new PHS Human Subject and Clinical Trial Information form. For application due dates of January 25, 2022, and beyond, you will be required to use an updated application forms package (FORMS-G), which includes the new human subject and clinical trial form. This form requests human subject and clinical trials information at the study level using discrete form fields, which is a change from current practice. Contract proposals will also require this information. Learn about the new form here. Second, take a moment to answer these four questions about your current or proposed research: If the answer to all four questions is yes, then your proposed research meets the NIH definition of a clinical trial. Clarified and broadened in 2014, the definition encompasses a wide range of trial types: mechanistic, exploratory/developmental, pilot/feasibility, behavioral, and more. NIH expanded the clinical trial definition in response to widespread calls from diverse stakeholders for improved reporting of research milestones and outcomes, and for assuring maximal transparency. Need help determining whether your study would be considered by NIH to be a clinical trial? See our webpage on the definition that includes case studies, FAQs and other resources that can help. Still unsure? Contact your NIH program official or the scientific point of contact listed on the funding opportunity announcement to which you are applying. Third, familiarize yourself with NIH policy changes related to enhancing stewardship of clinical trials. NIH made a number of policy changes to improve the stewardship of clinical trials across the life cycle of the trial. We encourage you to familiarize yourself with all that is changing, including: Improving the design, efficiency, and transparency of clinical trials is important because it: We have developed a new Clinical Trial Requirements for NIH Grantees and Contractors web page to bring together all the information you need to know. Please review this information carefully. Your attention to detail will be critical to ensuring successful funding of your clinical trial awards. We will be putting out a series of reminder policy notices, training opportunities, and other resources in the NIH Guide to Grants and Contracts, in the NIH Extramural Nexus, and on this blog. The success of clinical trials relies on the public trust in scientific rigor and ethical oversight. We all play a critical role in this process. We are most grateful to you for your help and support.
• write the research strategy and human subjects sections of your application
• comply with appropriate policies and regulations
1) Does the study involve human participants?
2) Are the participants prospectively assigned to an intervention?
3) Is the study designed to evaluate the effect of the intervention on the participants?
4) Is the effect that will be evaluated a health-related biomedical or behavioral outcome?
• the requirement to apply to an FOA that specifically allows for the submission of clinical trial applications for due dates beginning January 25, 2018.
• Good Clinical Practice training expectations for NIH staff, grantees, and contractors that went into effect January 2017.
• updated peer review criteria that will be included in FOAs for clinical trial applications and solicitations for due dates on/after January 25, 2018.
• new Human Subject Information form requirements for clinical trials that will be included in updated application forms (FORMS-G) for due dates on/after January 25, 2018, and contract solicitations published as of January 25, 2022.
• use of a single IRB for non-exempt, multi-site clinical trials for application due dates on/after January 25, 2018.
• expanded ClinicalTrials.gov registration and reporting to include all NIH supported clinical trials.
• respects our ethical obligation to participants to maximize the use of the knowledge from the trials in which they participate
• facilitates design of clinical trials while reducing unnecessary duplication
• promotes broad, timely, and responsible dissemination of research information and results
• fosters responsible stewardship of the public’s investment in biomedical research
If you are conducting NIH-funded research that involves human subjects, or are considering applying to NIH for support of such research, we want to call your attention to important changes that may affect how you:
• select the right NIH funding opportunity announcement
First, familiarize yourself with the new PHS Human Subject and Clinical Trial Information form. For application due dates of January 25, 2022, and beyond, you will be required to use an updated application forms package (FORMS-G), which includes the new human subject and clinical trial form. This form requests human subject and clinical trials information at the study level using discrete form fields, which is a change from current practice. Contract proposals will also require this information. Learn about the new form here.
Second, take a moment to answer these four questions about your current or proposed research:
If the answer to all four questions is yes, then your proposed research meets the NIH definition of a clinical trial. Clarified and broadened in 2014, the definition encompasses a wide range of trial types: mechanistic, exploratory/developmental, pilot/feasibility, behavioral, and more. NIH expanded the clinical trial definition in response to widespread calls from diverse stakeholders for improved reporting of research milestones and outcomes, and for assuring maximal transparency. Need help determining whether your study would be considered by NIH to be a clinical trial? See our webpage on the definition that includes case studies, FAQs and other resources that can help. Still unsure? Contact your NIH program official or the scientific point of contact listed on the funding opportunity announcement to which you are applying.
Third, familiarize yourself with NIH policy changes related to enhancing stewardship of clinical trials. NIH made a number of policy changes to improve the stewardship of clinical trials across the life cycle of the trial. We encourage you to familiarize yourself with all that is changing, including:
Improving the design, efficiency, and transparency of clinical trials is important because it:
We have developed a new Clinical Trial Requirements for NIH Grantees and Contractors web page to bring together all the information you need to know. Please review this information carefully. Your attention to detail will be critical to ensuring successful funding of your clinical trial awards. We will be putting out a series of reminder policy notices, training opportunities, and other resources in the NIH Guide to Grants and Contracts, in the NIH Extramural Nexus, and on this blog. The success of clinical trials relies on the public trust in scientific rigor and ethical oversight. We all play a critical role in this process. We are most grateful to you for your help and support.
Kate MacQueen, PhD, MPH
Kathleen (Kate) MacQueen is a Senior Scientist in Global Health Population Research at FHI 360. She has conducted extensive research on the social, behavioral and ethical aspects of biomedical HIV prevention trials globally and domestically, including vaccines, microbicides, vaginal rings and pre-exposure prophylaxis. Community engagement and partnership-building is a key component of her work. Domestically she has led participatory research projects focused on understanding and addressing HIV and other health disparities in Durham, NC. She has extensive collaborative international research experience including South Africa, Lesotho, Ghana, Nigeria, Cameroon, Thailand, and Vietnam. She has worked with a diverse range of populations to understand social, cultural and gender dynamics in their use of HIV prevention products. Dr. MacQueen has a PhD in anthropology from Binghamton University, MPH in health behavior from Emory University, and holds adjunct associate professorships at the University of North Carolina at Chapel Hill in the School of Medicine and the Gillings School of Public Health.
Audrey Pettifor, PhD
Dr. Audrey Pettifor is an epidemiologist whose research focuses on sexual behavior and determinants of HIV/STI infection in sub-Saharan Africa. Her goal is to identify modifiable risk factors and develop novel interventions to prevent new HIV infections—particularly among adolescents and young women.
Dr Pettifor has expertise in sexual behavior, HIV prevention, HIV testing and structural interventions among adolescents and young adults in sub-Saharan Africa, and has published extensively in the area of HIV and sexual behavior among youth in sub-Saharan Africa. Dr Pettifor has worked in South Africa for close to 20 years and has also conducted research in Malawi, Madagascar, Kenya, Zimbabwe and the Demographic Republic of Congo.
Cathy Emrick, MPH
Ms. Emrick serves as the Core liaison for Developmental applications and Awardees. Ms. Emrick has an MPH in Health Behavior and Health Education from UNC, and is the Program Coordinator For the UNC Center For AIDS Research (CFAR) Developmental Core. She has focused on the HIV epidemic since 1990, working in community-based organizations, state government, and research at UNC.
2020 Developmental Awardees
|Dr. Guochun Jiang, HIV Cure Center||Dr. Abigail Hatcher, UNC Gillings School||Dr. Lauren Hill, UNC Gillings School||Dr. Sarah Rutstein, UNC Infectious Diseases|
|HIV reservoirs in the central nervous system||Towards a therapeutic intervention for pregnant adolescents living with HIV and partner violence||Developing an Online PrEP Shared Decision-Making Aid for US Women||Genomics of Genital Ulcer Disease of Unknown Etiology Among Persons with HIV or at High Risk for HIV-infection in Malawi|
Request for Proposals for Developmental Awards
The UNC CFAR Developmental Core provides Developmental Awards and small secondary data analysis awards to emerging HIV investigators for one year of research.
Q: What types of feedback does the CFAR Developmental Review Committee give to applicants?
A: There are definitely themes that we frequently see across applications, disciplines, and years. Common positive feedback includes:
Project is signifigant, scientifically interesting
The proposal includes strong mentors
The hypothesis is plausible and novel
Common negative feedback includes:
The proposal and intervention are too ambitious
PI needs guidance with methods
The analysis plan was lacking
The sample size is too small
No power calculations were discussed
The intervention may be too diffuse
No clear path to follow-up NIH funding
Much of the negative feedback could be avoided by active engagement with the PI’s mentor during the application process. In addition, both the CFAR Biostatistics Core and Sonia Napravnik of the CFAR Clinical Core are willing to assist applicants with their methodology and/or analysis plans. The Social and Behavioral Science Core is also willing to help by looking at intervention ideas and social/behavioral methodology. We strongly recommend applicants utilize these resources before submitting their proposals – applications that have been through these steps prior to final submission tend to be more competitive.
Q: A mentor sounds useful. How do I get one of those?
A: If you have one or more already, feel free to use them. We understand the value of a mentoring team that may include a senior investigator who specializes in the science or methodology utilized by your proposal, another who knows your population or topic area, and perhaps another who has your dream career and can help you plan how to achieve one just like it. If, however, you have not yet found a mentor that is a good fit for you and your research goals, don’t worry – we can help! We could probably make some recommendations based on a conversation with you, but it would be even better if you had some ideas already. We suggest that you go to the NIH RePORTER and search for investigators based on location (ideally UNC, FHI, or RTI), topic area (e.g., HCV and HIV, medication adherence and HIV, or whatever you are interested in), and NIH Institute that you think is the best fit for you. After all, wouldn’t it be great to have a mentor that already knows the project officers, interests, quirks, etc., of your favorite Institute? If they have already figured out how to succeed in your area and Institute, they might be a good person to seek out for advice. Find a few people that fit those criteria if you can, and then email us with those names. We’ll facilitate your interactions with them and see if we can’t help get you one of those useful mentors.
Tips on choosing a mentor from NIH: https://www.niaid.nih.gov/grants-contracts/tips-choosing-mentor
Q: Are overhead/indirect costs or PI salary support allowed in the Developmental proposal budget? [THIS POLICY HAS CHANGED]
A: It is our policy not to provide indirect costs at research-based colleges or universities. The UNC SOM similarly donates their share of the indirect costs back into the Award funds to maximize their reach.
However, PI salary support is now allowed for ALL ESI applicants. The amount should be carefully considered and thoroughly justified, and fall within the total budget limitations. As the application and amount of time that the applicant needs to be devoted to the proposed project is being developed, keep in mind that 10% LOE equals one half day a week, and 20% LOE equals one full day a week, and prepare the budget justification accordingly. Applicants are not required to request salary support and all justifications including salary support will be thoroughly reviewed.
Q: What’s a SWG?
A: The UNC CFAR is committed to fostering interdisciplinary collaboration among research investigators, and provides the support and resources necessary for investigators to work together in pursuit of unique research topics. UNC CFAR’s Scientific Working Groups (SWGs) are comprised of investigators who share common research interests and goals, and participate in competitively funded research.
One of the CFAR’s missions is to support the work of our SWGs, so we like to see new interdisciplinary research come out of these groups and encourage that by offering them money. Currently, our CFAR has one SWG:
Carolinas United to End HIV, or CUE-HIV (Lauren Brinkley-Rubinstein and Kimberly Powers, co-Chairs)
If you like the idea of a Developmental Award and share their research interests, the SWGs are always open to new members!
If you like the idea of a Developmental Award and share their research interests, the SWGs are always open to new members!
Q: I’m a post-doc/fellow and really need some money for a great HIV-related project. May I apply?
A: We appreciate post-docs/fellows and would love to help all of you but unfortunately our funds are limited. Since the CFAR’s continued funding depends in part on how successful our Developmental Awardees are at getting R and K level awards, and federal research funds are becoming harder to come by, we have to give preference to applications that will lead to an R or K level award and also ultimately lead to publication of Developmental data. In other words, while we are not currently completely ruling out post-doc applications at this time, strong preference is given to ESI faculty.
Q: I’m not a early stage researcher, but I haven’t worked in HIV before. Don’t you want to help me?
A: Of course we do! In fact, we love to lure in senior investigators from other fields… I mean, help them expand their research interests. The application process is the same as for early stage investigators, as are the required documentation and outcomes. If you have already been PI on an R01 for a project in HIV, however, you are already one of us and we cannot lure, ahem, fund you.
Q: My research interests align with NIH’s priorities and will lead to an R01, I’m sure of it. Is that all I need to say about that?
A: No, of course not! Tell us more – we want to hear all about it. To which institute will you be applying? Convince us that you and the NIH are soulmates, destined to come together in the relatively near future. We want a very specific funding path, a plan outlining how the proposed work will lead to NIH funding, a timeline for seeking such funding, the NIH institute or center from which you anticipate seeking funding, and the type of grant you plan to pursue (one page maximum, and not part of four page grant text limit). With which of NIH’s priorities does your project align? Your application must also include a separate document explaining how the proposed work is aligned with the NIH priorities. This document does not count toward the four-page grant text limit either.
Q: Talk to me about CFAR Administrative Supplements.
A: About once a year, NIH announces opportunities for CFAR Administrative Supplements. The RFA targets a short list of specific areas of HIV research that are generally up to about $100,000-$150,000 for one year. Each CFAR may submit one application per topic area to the NIH, so if more than one researcher is interested in a particular topic, we will do an internal review of letters of intent and choose one that can then move forward into a full application.
Q: That’s a lot more money than a CFAR Developmental Award. Can I apply for a CFAR Administrative Supplement?
A: Only if your research idea is in an area of interest for this year’s Administrative Supplement RFA and you get the go-ahead from the CFAR leadership. Eligible applicants should also keep in mind that Supplement proposals must clear three hurdles at NIH – 1) they have to be strong enough in their science and methodology to be selected for funding; 2) the UNC CFAR must not have a significant anticipated amount of carryover into the next fiscal year, or else NIH will tell us to go fund it ourselves – which, since carryover is always spoken for, we generally cannot do (which is why we are constantly reminding our funded ESIs to spend their money as fast as they reasonably can!); and 3) pay attention here – they have to be about HIV/AIDS! NIH will no longer fund non-AIDS projects with AIDS money. So if it is going through the Office of AIDS Research (as CFAR Administrative Supplements must), it had better have HIV or AIDS in its title. There are many STIs and IDs that are important in the world of HIV, but they are no longer going to be funded through the OAR. So if you want a CFAR Administrative Supplement, be sure you state clearly in the application and title that it is going to be HIV/AIDS research.
Q: What are the PI requirements for an Administrative Supplements?
A: They are similar to those of the Developmental Awards, i.e., you must be eligible to serve as a PI on an R level NIH grant, and you must be associated in some way with the CFAR through which you are applying (hence the requirement of the CFAR PI’s approval). The primary desired Supplement outcome is a larger, directly related NIH grant. The gold standard is an R01. The primary difference between Developmental funding applicants and Supplement applicants is that the latter are not required to be ESIs, although we are still quite partial to ESIs. Regardless, we will be closely watching – and reporting on – Administrative Supplement PIs’ success(es), so that the NIH and Congress will see how important it is that they continue to provide CFAR and Supplemental funding.
Q: OK, so let’s say I get funding from a CFAR Developmental Award or a CFAR Administrative Supplement. What do YOU get out of it?
A: Well, if you can cure AIDS, that’d be good. But even if you can’t (yet), what we want is for you to succeed. Our goal is to help early stage investigators build their HIV research careers and make a difference in this epidemic. As Charlie always said, we are training our replacements. As Kate says, we can see the light at the end of the tunnel now but the next generation of researchers is going to get to actually walk out into that light.
Of course, to justify our CFAR’s continued funding from NIH, we have to provide evidence that we are on the right track. As mentioned above, the primary desired outcome is always a larger, directly related NIH grant. The gold standard is an NIH R01 (or a less common “R01 equivalent”, i.e., R23, R29, or R37) grant, and that is what all of our Awardees and Administrative Supplement PIs should strive for. However, any post-Award funding that is directly related to your CFAR award is positive achievement and should be reported proudly back to the Developmental Core so that we can effectively brag about it to NIH and anyone else who will listen. An R21, for example, can be an intermediate step toward an R01 and may be easier to attain first. Funding from CDC or other sources is also nice, although less desirable as far as our needed outcomes as funding from NIH. In summary, smaller follow up funding is great, but keep your eye on the R01 as your ultimate goal.
We also need for you to share your CFAR research results with the scientific community. We are all partners in the fight against AIDS and sharing information makes us all stronger. Therefore, our other desired outcome for all CFAR-funded research is dissemination of results. The gold standard in this outcome category is publication in a peer review journal (citing the CFAR, linking it to our grant, and obtaining a PMCID are all required), but as an intermediate step, we accept the presentation of research at national and/or international conferences. Again, keep your eye on the prize – plan to publish.
Your mentor can play a key role in helping you achieve each of these outcomes. We can help as well. You have the support of an incredible HIV research community behind you – utilize us! In fact, even if you are not a Developmental Awardee or Administrative Supplement PI, if you are a early stage investigator in the CFAR, we want to help you succeed.
Remember, we will be closely watching – and reporting on – your success(es), so that the NIH and Congress will see how important it is that they continue to provide CFAR and Supplemental funding.
Q: Is there any guidance on-line about writing an NIH grant proposal?
Yes, in fact, there is! NIAID has great detailed information on-line.
Q. I want to do an RCT but I’m not sure whether it’s actually considered to be “clinical trial” per se. Does that really matter?
A. Projects involving clinical research (e.g., observational studies or sub-studies using existing data from an ongoing clinical trial) may be funded by the CFAR.However, CFARs are not allowed to fund clinical trials. The NIH definition of a clinical trial is very broad. Some investigators conducting human subjects research may not be aware that NIH considers their study to be a clinical trial. To find out for sure, click here. Applicants considering submission of proposals that might be considered clinical trials are strongly encouraged to seek advice from CFAR Developmental Core Director Dr. Kate MacQueenbefore submitting a proposal.
Q. What happens next, after I find out that my [Developmental or Supplement] application is going to be funded? Other than celebrations on both sides, of course.
A. A whole lot of paperwork. I’m not gonna lie, there are a ton of documents that you will be required to complete before we are allowed to release your funds, most having to do with human subjects
Obviously, you must forward a copy of all current Institutional Biohazard, Animal Care, and IRB approvals to the CFAR Developmental Core. All projects must be approved by the UNC-Chapel Hill IRB, even if the Awardee/PI is elsewhere. If there are two domestic IRBs that should be involved, Tonia Hossain and her team will help you put together an IAA form for one of them, authorizing the other to be the one to make a judgement on the project.
You and your mentor(s) will need to sign a mentor-mentee contract to be sure that everyone involved understands what we require your relationship to look like. And for sure we want your photograph to put on our website to show everyone how cool our newly funded folks are!
If your research involves human subjects and the UNC and/or international IRB/Ethics Committee has deemed the study “more than minimal risk”, projects must receive NIH Clinical Clearance before funding is released. If your project is international, you will also need NIH International Clearance. Don’t worry, though – it takes a while to complete, but the Dev Core will guide you through every step of the process. For example, we will give you an example of a detailed SOP that the NIH loved to serve as a template for yours. The Human Subjects Study form is likewise very detailed and time-consuming to put together, but we will give you a guidance document to explain every question on the form. You will be required to send us documentation that all of your research team has completed research ethics training (e.g., CITI training). Etc. But again, I promise we will help you through that painful process (and believe me, it is painful for all of us!).
The NIH requirements for Developmental Awards and Supplements are far more demanding than for other NIH-funded awards simply because the applications don’t go through peer review at NIH before they are funded. Therefore, in order to fulfill their responsibility to ensure that all NIH-funded projects are conducted ethically, they must require a lot more documentation – that they seriously go through extremely carefully! – after the funding decisions are made but before the start of the research. In other words, after your Award notification but before we are allowed to release your funds. They are very strict about receiving and reviewing all of the documentation before the research starts – if we start a project without getting all of the necessary approvals, the NIH has the power to shut down the CFAR as a whole. Please let’s not do that. As the mother of a child might say, that’s the wrong kind of attention to seek.
Visit our CFAR Notice of Special Interest (NOSI): Request for Proposals for HIV/COVID-19 Small Grants page for more information.
Visit our UNC CFAR Secondary Data Analysis NOSI page for more information.
Filiatreau LM, Wright M, Kimaru L, Gomez-Olive FX, Selin A, Twine R, Kahn K and Pettifor A. Correlates of ART Use Among Newly Diagnosed HIV Positive Adolescent Girls and Young Women Enrolled in HPTN 068. AIDS Behav.:[Epub ahead of print]. 2020.
Graybill LA, Kasaro M, Freeborn K, Walker JS, Poole C, Powers KA, Mollan KR, Rosenberg NE, Vermund SH, Mutale W and Chi BH. Incident HIV among pregnant and breastfeeding women in sub-Saharan Africa: a systematic review and meta-analysis. AIDS. 34(5):761-776. 2020. PMC7275092.
Hoang T, Toler E, DeLong K, Mafunda NA, Bloom SM, Zierden HC, Moench TR, Coleman JS, Hanes J, Kwon DS, Lai SK, Cone RA and Ensign LM. The cervicovaginal mucus barrier to HIV-1 is diminished in bacterial vaginosis. PLoS Pathog. 16(1):e1008236. 2020. PMC6999914.
Lancaster KE, Lungu T, Bula A, Shea JM, Shoben A, Hosseinipour MC, Kohler RE, Hoffman IF, Go VF, Golin CE, Wheeler SB and Miller WC. Preferences for Pre-exposure Prophylaxis Service Delivery Among Female Sex Workers in Malawi: A Discrete Choice Experiment. AIDS Behav. 24(5):1294-1303. 2020. [PMCID in process].
Montgomery ND, Randall C, Painschab M, Seguin R, Kaimila B, Kasonkanji E, Zuze T, Krysiak R, Sanders MK, Elliott A, Miller MB, Kampani C, Chimzimu F, Mulenga M, Damania B, Tomoka T, Fedoriw Y, Dittmer DP and Gopal S. High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi. Cancer Med. 9(2):552-561. 2020. PMC6970037.
Pan SW, Carpiano RM, Smith MK, Ong JJ, Fu H, Huang W, Tang W and Tucker JD. Supernatural explanatory models of health and illness and healthcare use in China among men who have sex with men. Glob Public Health. 15(1):83-96. 2020. PMC6934899.
Sellers SA, Dover KL, Bailey AG, Cheves A, Eason AB, Popowitch EB, Miller MB, Wohl DA, Dittmer DP and Fischer WA. Burden of respiratory viral infection in persons with human immunodeficiency virus. Influenza Other Respir Viruses. 2020. PMC7298306.
Wesevich A, Hosseinipour MC, Golin CE, McGrath N, Tsidya M, Chimndozi L, Bhushan N, Hoffman I, Miller WC and Rosenberg NE. Female adherence self-efficacy before and after couple HIV testing and counseling within Malawi’s Option B+ program. AIDS Care. 32(2):170-174. 2020. PMC7302401.
Youngblood VM, Nyirenda R, Nyasosela R, Zuze T, Yang Y, Kudowa E, Moses A, Kincaid J, Kajombo C, Kampani C, Chimzimu F, Mulenga M, Chilima C, Ellis GK, Seguin R, Chagomerana M, Maine R, Jordan S, Charles A, Lee C, Gopal S and Tomoka T. Outcomes and prognostic factors for women with breast cancer in Malawi. Cancer Causes Control. 31(4):393-402. 2020. PMC7115156.
Conserve DF, Issango J, Kilale AM, Njau B, Nhigula P, Memiah P, Mbita G, Choko AT, Hamilton A, King G (2019). Developing national strategies for reaching men with HIV testing services in Tanzania: results from the male catch-up plan. BMC Health Serv Res;19(1):317.
Costenbader E, Cislaghi B, Clark CJ, Hinson L, Lenzi R, McCarraher DR, McLarnon-Silk C, Pulerwitz J, Shaw B, Stefanik L (2019). Social Norms Measurement: Catching up with Programs and Moving the Field Forward. J Adol Health;64(4):S4-S6.
Eley NT, Namey E, McKenna K, Johnson AC, Guest G (2019). Beyond the Individual: Social and Cultural Influences on the Health-Seeking Behaviors of African American Men. Am J Men’s Health;13(1):1-11.
Ewing AC, Davis NL, Kayira D, Hosseinipour MC, van der Horst C, Jamieson DJ, Kourtis AP; Breastfeeding, Antiretrovirals and Nutrition study team (2019). Prescription of Antibacterial Drugs for HIV-Exposed, Uninfected Infants, Malawi, 2004-2010. Emerg Infect Dis;25(1):103-112.
Hershow RB, Gonzalez M, Costenbader E, Zule W, Golin C, Brinkley-Rubinstein L (2019). Medical Providers and Harm Reduction Views on Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs. AIDS Educ Prev;31(4):363-379.
Knittel AK, Lambdin BH, Comfort ML, Kral AH, Lorvick J (2019). Sexual Risk and Criminal Justice Involvement Among Women Who Use Drugs. AIDS Behav; doi: 10.1007/s10461-019-02447-2. [Epub ahead of print].
Knittel AK, Michel K, Milam J, Cohen J, Donohue J, Foster A, Fischl M, Konkle-Parker D, Adimora AA (2019). The effects of incarceration on sexually transmitted infections in women with or at risk for HIV in the United States. International Workshop on HIV and Hepatitis Observational Databases, Athens, Greece.
Knittel AK, Shook-Sa BE, Rudolph JE, Edmonds A, Ramirez C, Adimora AA (2019). Incarceration in women at risk for HIV. American College of Obstetrics and Gynecology Annual Meeting, Nashville, TN.
Lancaster KE, Lungu T, Bula A, Shoben A, Hosseinipour MC, Kohler RE, Hoffman IF, Go VF, Golin CE, Wheeler SB, Miller WC (2019). Preferences for PrEP delivery among FSW in Malawi using a discrete choice experiment. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA.
Masa R and Chowa G (2019). The Association of Material Hardship with Medication Adherence and Perceived Stress Among People Living with HIV in Rural Zambia. Glob Soc Welf; 6(1): 17–28.
Pillay ST, Nag M, Fogle JE, De Paris K (2019). The Epigenetic Profile of CD8+ T Cells During SIV Infection. Immunology 2019 (American Association of Immunologists, Annual Meeting), San Diego, CA.
Shea J, Bula A, Dunda W, Hosseinipour MC, Golin CE, Hoffman IF, Miller WC, Go VF, Lungu T, Lancaster KE (2019). “The Drug Will Help Protect My Tomorrow”: Perceptions of Integrating PrEP into HIV Prevention Behaviors Among Female Sex Workers in Lilongwe, Malawi. AIDS Educ Prev;31(5):421-432.
Wu D, Tang W, Lu H, Zhang TP, Cao B, Ong JJ, Lee A, Liu C, Huang W, Fu R, Li K, Pan SW, Zhang Y, Fu H, Wei C, Tucker JD (2019). Leading by Example: Web-Based Sexual Health Influencers Among Men Who Have Sex With Men Have Higher HIV and Syphilis Testing Rates in China. J Med Internet Res;21(1):e10171.
Yotebieng M, Brazier E, Addison D, Kimmel AD, Cornell M, Keiser O, Parcesepe AM, Onovo A, Lancaster KE, Castelnuovo B, Murnane PM, Cohen CR, Vreeman RC, Davies MA, Duda SN, Yiannoutsos CT, Bono RS, Agler R, Bernard C, Syvertsen JL, Sinayobye JD, Wikramanayake R, Sohn AH, von Groote PM, Wandeler G, Leroy V, Williams CF, Wools-Kaloustian K, Nash D, IeDEA Treat All in sub-Saharan Africa Consensus Statement Working Group (2019). Research priorities to inform “Treat All” policy implementation for people living with HIV in sub-Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS (IeDEA). J Int AIDS Soc;22(1):e25218.
Billock RM, Samoff E, Cope AB, Sampson LA, Hurt CB, Powers KA (2018). Repeat HIV testing by transmission risk group and rurality of residence in North Carolina. Sex Tran Dis;45(10):684-689.
Bradley T, Ferrari G, Haynes BF, Margolis DM, Browne EP (2018). Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. Cell Rep;25(1):107-117.e3.
Bula A, Kopp DM, Maman S, Chinula L, Tsidya M, Tang JH (2018). Family planning knowledge, experiences and reproductive desires among women who had experienced a poor obstetric outcome in Lilongwe Malawi: a qualitative study. Contracept Reprod Med;3:22.
Cameron JE, Rositch AF, Vielot NA±, Mugo NR, Kwatampora JKL, Waweru W, Gilliland AE, Hagensee
ME, Smith JS (2018). Epstein-Barr virus, high-risk human papillomavirus and abnormal cervical cytology
in a prospective cohort of African female sex workers. Sexually Transmitted Diseases. Epub ahead of
Chagomerana MB, Miller WC, Tang JH, Hoffman IF, Harrington BJ, DiPrete B, Wallie S, Jumbe A, Limarzi L, Hosseinipour MC (2018). Prevalence of antiretroviral therapy treatment failure among HIV-infected pregnant women at first antenatal care: PMTCT Option B+ in Malawi. PLoS One;13(12):e0209052.
Chagomerana MB, Miller WC, Tang JH, et al. (2018). Optimizing prevention of HIV mother to child transmission:
Duration of antiretroviral therapy and viral suppression at delivery among pregnant Malawian women.
Chinula L, Nelson JAE, Wiener J, Tang JH, Hurst S, Tegha G, Msika A, Ellington S, Hosseinipour MC, Mataya R, Haddad LB, Kourtis AP (2018). Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial. Contraception;98(3):193-98.
Conserve DF, Alemu D, Yamanis T, Maman S, Kajula L (2018). “He Told Me to Check My Health”: A Qualitative Exploration of Social Network Influence on Men’s HIV Testing Behavior and HIV Self-Testing Willingness in Tanzania. Am J Mens Health;12(5):1185-1196.
Conserve DF, Muessig K, Maman S, Kajula S (2018). Mate Yako Afya Yako: Formative Research to Develop the Peer-Based HIV Self-Testing Education and Promotion (STEP) Intervention for Networks of Men in Tanzania. Plos One Journal;13(8):e0202521.
Davey DJ, Peters RPH, Kojima N, Mudau M, De Vos L, Olivier D, McIntyre JA, Klausner JD, Medina-Marino A (2018). Sexual behaviors of HIV-infected pregnant women and factors associated with sexual transmitted infection in South Africa. Sex Transm Dis;45(11):754-761.
Dennis AM, Pasquale DK, Billock R, Beagle S, Mobley V, Cope A, Kuruc J, Sebastian J, Walworth C,
Peone PA (2018). Integration of Contact Tracing and Phylogenetics in an Investigation of an Acute
Infection. Sex Transm Dis;45(4):222-228.
Francis DB, Noar SM, Fortune DA, Adimora AA (2018). Evaluation of a novel condom distribution and health communication intervention targeting young African American females. 15th Biennial Kentucky Conference on Health Communication, Lexington, KY.
Gausi B, Chagomerana MB, Tang JH, Hosseinipour MC, Haddad LB, Hannock T, Phiri S (2018). Human Immunodeficiency Virus Serodiscordance and Dual Contraceptive Method Use Among Human Immunodeficiency Virus-Infected Men and Women in Lilongwe, Malawi. Sex Transm Dis;45(11):747-753.
Herce ME, Miller WM, Bula A, Edwards JK, Sapalalo P, Lancaster KE, Mofolo I, Furtado MLM, Weir SS (2018). Achieving the first 90 for key populations in sub-Saharan Africa through venue-based outreach: challenges and opportunities for HIV prevention based on PLACE study findings from Malawi and Angola. J Int AIDS Soc;21(Suppl 5):e25132.
Hermes DJ, Xu C, Poklis JL, Niphakis MJ, Cravatt BF, Mackie K, Lichtman AH, Ignatowska-Jankowska BM, Fitting S (2018). Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS. Neuropharmacology;141:55-65.
Kayongo A, Gonzalo-Gil E, Gümüşgöz E, Niwaha AJ, Semitala F, Kalyesubula R, Bagaya BS, Joloba ML, Sutton RE (2018). Brief Report: Identification of Elite and Viremic Controllers from a Large Urban HIV Ambulatory Center in Kampala, Uganda. J Acquir Immune Defic Syndr;79(3):394-398.
Ke R, Conway JM, Margolis DM, Perelson AS (2018). Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. JCI Insight;3(20): e123052.
Kopp DM, Bula A, Maman S, Chinula L, Tsidya M, Mwale M, Tang JH (2018). Influences on birth spacing intentions and desired interventions among women who have experienced a poor obstetric outcome in Lilongwe Malawi: a qualitative study. BMC Pregnancy Childbirth;18(1):197.
Kovarova M, Benhabbour SR, Massud I, Spagnuolo RA, Skinner B, Baker CE, Sykes C, Mollan KR, Kashuba ADM, García-Lerma JG, Mumper RJ, Garcia JV (2018). Ultra-long-acting removable drug delivery system for HIV treatment and prevention. Nat Commun;9(1):4156.
Lancaster KE, Hetrick A, Jaquet A, Adedimeji A, Atwoli L, Colby DJ, Mayor AM, Parcesepe A, Syvertsen J (2018). Substance use and universal access to HIV testing and treatment in sub-Saharan Africa: implications and research priorities. J Virus Erad;4(Suppl 2):26-32.
Lockhart A, Psioda M, Ting J, Campbell S, Mugo N, Kwatampora J, Chitwa M, Kimani J, Gakure A, Smith
JS (2018). Prospective evaluation of cervico-vaginal self and cervical physician-collection for the detection
of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium
infections. Sexually Transmitted Diseases. Epub ahead of print.
Matoga MM, Rosenberg NE, Stanley CC, LaCourse S, Munthali CK, Nsona DP, Haac B, Hoffman I,
Hosseinipour MC (2018). Inpatient mortality rates during an era of increased access to HIV testing and
ART: A prospective observational study in Lilongwe, Malawi. PLoS One;13(2):e0191944.
Matoga M, Mmodzi P, Massa C, Bula A, Hosseinipour M, Chasela C (2018). Health System Factors Influencing Partner Notification for STIs and HIV in Lilongwe Malawi. A Pre-Intervention Phase Assessment for a Quality Improvement Project. J Infect Dis Med;3(1):125.
Mbichila TH, Chagomerana M, Tang JH, Haddad LB, Hosseinipour MC, Tweya H, & Phiri S. (2018). Partnership duration and HIV serodisclosure among people living with HIV/AIDS in Lilongwe, Malawi. International Journal of STD & AIDS;29(10), 987–993. PMID: 29743000
Ngongondo M, Miyahara S, Hughes MD, Sun X, Bisson GP, Gupta A, Kumwenda J, Lavenberg JA, Torres TS, Nyirenda M, Kidonge KK, Hosseinipour MC; AIDS Clinical Trials Group A5274 (REMEMBER) Study Team (2018). Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living with HIV with Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. J Acquir Immune Defic Syndr;78(1):54-61.
Ngongondo M, Rosenberg NE, Stanley CC, Lim R, Ongubo D, Broadhurst R, Speight C, Flick R, Tembo P, Hosseinpour MC (2018). Anemia in people on second line antiretroviral treatment in Lilongwe, Malawi: a cross-sectional study. BMC Infect Dis;18(1):39.
Nwaohiri AN, Tang JH, Stanczyk F, Chinula L, Hurst S, Davis NL, Tegha G, Haddad L, Kourtis AP (2018).
Discordance between self-reported contraceptive use and detection of exogenous hormones among
Malawian women enrolled in a randomized controlled trial. Contraception;97(4):354-6.
Sullivan KA, Little M, Rosenberg NE, Mtande T, Zimba C, Jaffe E, Anderson J, Coleman JS, Gilbert S, Gross Wolf MS, Hoffman I, Rahangdale L, Faden R, Lyerly AD (2018). Women’s Views About a Paternal Consent Requirement for Biomedical Research in Pregnancy. J Empir Res Hum Res Ethics;13(4):349-362.
Tang JH, Lemani C, Nkambule J, Talama G, Banda C, Zgambo W, Chagomerana M (2018). Two-year contraceptive continuation rates among immediate postpartum implant users at a district hospital in Malawi: a prospective cohort study. Contraception;98(3):220-222.
Torres TS, Harrison LJ, La Rosa AM, Cardoso SW, Zheng L, Ngongondo M, Some F, Lalloo UG, Mwelase T, Collier AC, Hughes MD; AIDS Clinical Trials Group (ACTG) A5273 Study Group (2018). Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS;32(5):583-593.
Torres TS, Harrison LJ, La Rosa AM, Lavenberg JA, Zheng L, Safren SA, Ngongondo M, Poongulali S, Matoga M, Samaneka W, Collier AC, Hughes MD (2018). Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings. AIDS Care;30(8):954-962.
Wood D, Lancaster KE, Boily MC, Powers KA, Donnell D, Cohen MS, Dimitrov DT (2018). Recruitment of Female Sex Workers in HIV Prevention Trials: Can Efficacy Endpoints Be Reached More Efficiently? J Acquir Immune Defic Syndr;77(4):350-357.
Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, Kashuba AD, Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM (2017). Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J Clin Invest;127(8):3126-3135.
Costenbader E, Mangone E, Mueller M, Parker C, MacQueen KM (2017). Rapid organizational network
analysis to assess coordination of services for HIV testing clients: An exploratory study, J HIV/AIDS & Soc
Services. Online 15 Dec 2017.
Croffut SE, Hamela G, Mofolo I, Maman S, Hosseinipour MC, Hoffman IF, Bentley ME, and Flax VL (2017). HIV-positive Malawian women with young children prefer overweight body sizes and link underweight body size with inability to exclusively breastfeed. Matern Child Nutr. [Epub ahead of print].
Dennis AM, Hue S, Learner E, Sebastian J, Miller WC, Eron JJ (2017). Rising prevalence of non-B HIV-1
subtypes in North Carolina and evidence for local onward transmission. Virus Evol;3(1):vex013.
Flax VL, Hamela G, Mofolo I, Hosseinipour MC, Hoffman I, and Maman S (2017). Factors influencing postnatal Option B+ participation and breastfeeding duration among HIV-positive women in Lilongwe District, Malawi: a qualitative study. PLoS One;12(4):e0175590.
Goeieman BJ, Firnhaber CS, Jong E, Michelow P, Swarts A, Williamson AL, Allan B, Smith JS, Kegorilwe P, and Wilkin TJ (2017). Prevalence Of Anal HPV And Anal Dysplasia In HIV-Infected Women From Johannesburg, South Africa. J Acquir Immune Defic Syndr;75(3):e59-e64.
Kourtis AP, Haddad L, Tang J, Chinula L, Hurst S, Wiener J, Ellington S, Nelson JA, Corbett A, De Paris K, King CC, Hosseinipour M, Hoffman IF, and Jamieson DJ (2017). A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities. Contemp Clin Trials;52:27-34.
Masa R and Chowa G (2017). A multi-level conceptual framework to understand the role of food insecurity on antiretroviral therapy adherence in low-resource settings: From theory to practice. Social Work in Public Health;32(5):324-338.
Masa R, Chowa G, and Nyirenda V (2017). Prevalence and predictors of food insecurity among people living with HIV enrolled in antiretroviral therapy and livelihood programs in two rural Zambian hospitals. Ecology of Food and Nutrition;56(3):256-276.
Masa R, Chowa G, and Nyirenda V (2017). Barriers and facilitators of antiretroviral therapy adherence in rural Eastern Province, Zambia: The role of household economic status. African Journal of AIDS Research;16(2):91-99
Sellers SA, Chason KD, Fischer WA (2017). Respiratory Mucosal Immune Suppression in HIV-Infected Individuals. Infectious Disease Society of America Meeting, San Diego, CA.
Sellers SA, Dover K, Wohl DA, Miller M, Dittmer D, Fischer WA (2017). The Burden of Respiratory Viral Illness in HIV Infected Patients. American Thoracic Society Meeting, Washington, DC.
Sin S-H, Eason B, Kim Y, Kang S, An H, and Dittmer DP (2017). Hyperglobulinemia in KSHV latency mice is prevented by everolimus. 20th International Workshop on KSHV and Related Agents, Berlin, Germany.
Vogt SL, Moosa P, Omar T, Pather S, Martinson N, Ambinder RF (2017). Molecular diagnostics for AIDS lymphoma diagnosis in South Africa and the potential for other low-and middle-income countries. J Glob Oncol;4:1-6.
Xu C, Hermes DJ, Nwanguma B, Jacobs IR, Mackie K, Mukhopadhyay S, Lichtman AH, Ignatowska-
Jankowska B, Fitting S (2017). Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in
models of neuronal damage induced by HIV-1 Tat protein. Mol Cell Neurosci;83:92-102.
Firnhaber C, Goeieman B, Faesen M, Levin S, Williams S, Rameotshela S, Swarts A, Michelow P, Omar T, Williamson AL, Allan B, Schnippel K, and Smith JS (2016). Prospective One Year Follow Up of HIV Infected Women Screened for Cervical Cancer Using Visual Inspection with Acetic Acid, Cytology and Human Papillomavirus Testing in Johannesburg South Africa. PLoS One;11(1):e0144905.
Flax VL, Hamela G, Mofolo I, Hosseinipour MC, Hoffman I, Maman S (2016). Infant and young child feeding counseling, decision-making, and practices among HIV-infected women in Malawi’s Option B+ prevention of mother-to-child transmission program: a mixed methods study. AIDS & Behavior;20(11):2612-2623.
Krubiner CB, Faden RR, Cadigan RJ, Gilbert SZ, Henry LM, Little MO, Mastroianni AC, Namey EE, Sullivan KA, and Lyerly AD (2016). Advancing HIV research with pregnant women: navigating challenges and opportunities. AIDS;30(15):2261-5.
Mouw MS, Taboada A, Steinert S, Willis S, Lightfoot AF (2016). “Because We All Trust and Care about Each Other”: Exploring Tensions Translating a Theater-based HIV Prevention Intervention into a New Context. Prog Community Health Partnersh. 2016;10(2):241-9.
Oramasionwu CU, Kashuba AD, Napravnik S, Wohl DA, Mao L, Adimora AA (2016). Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection. World J Hepatol. 8:368-75.
Rosenberg NE, Stanley CC, Rutstein SE, Bonongwe N, Kamanga G, Pettifor A, Mapanje C, Martinson F, Hoffman IF, and Miller WC (2016). Recruiting the Social Contacts of STI Patients for HIV Screening in Lilongwe, Malawi: Process Evaluation and Assessment of Acceptability. Sex Transm Infect;92(8):587-592.
Taboada A, Taggart T, Holloway I, Houpt A, Gordon R, Gere D, Milburn N, Lightfoot AF (2016). A Critical Review of the Characteristics of Theater-Based HIV Prevention Interventions for Adolescents in School Settings. Health Promot Pract. 17(4):537-47.
Taggart T, Taboada A, Stein JA, Milburn NG, Gere D, Lightfoot AF (2016). AMP!: A Cross-site Analysis of the Effects of a Theater-based Intervention on Adolescent Awareness, Attitudes, and Knowledge about HIV. Prev Sci. 17(5):544-53.
Caldwell K and Matthews A (2015). The Role of Relationship Type, Risk Perception, and Condom Use in
Middle Socioeconomic Status Black Women’s HIV-prevention Strategies. J of Black Sexuality and
Grewe ME, Taboada A, Dennis A, Chen E, Stein K, Watson S, Barrington C, Lightfoot AF (2015). ‘I learned to accept every part of myself’: the transformative impact of a theatre-based sexual health and HIV prevention programme. Sex Educ;15(3):303-317.
Herce ME, Mtande T, Chimbwandira F, Mofolo I, Chingondole CK, Rosenberg NE, Lancaster KE, Kamanga E, Chinkonde J, Kumwenda W, Tegha G, Hosseinipour MC, Hoffman IF, Martinson FE, Stein E, van der Horst CM (2015). Supporting Option B+ scale up and strengthening the prevention of mother-to-child transmission cascade in central Malawi: results from a serial cross-sectional study. BMC Infect Dis;15:328.
Juliano JJ, Barnett E, Parobek CM, Taylor SM, Meshnick SR, Stone S, Chang, E, Fong S, and Huang L (2015). Use of Oropharyngeal Washes to Diagnose and Genotype Pneumocystis jirovecii. Open Forum Infect Dis; 2(3):ofv080.
LaCourse SM, Chester FM, Matoga M, et al. (2015). Implementation of routine counselor-initiated opt-out HIV testing on the adult medical ward at Kamuzu Central Hospital, Lilongwe, Malawi. J Acquir Immune Defic Syndr; 69(1):e31-5.
Lesko CR, Sampson LA, Miller WC, Clymore J, Leone PA, Swygard H, Powers KA (2015). Measuring the HIV care continuum using public health surveillance data in the United States. Journal of Acquired Immune Deficiency Syndromes.70(5): 489-494.
Lightfoot AF, Taboada A, Taggart T, Tran T, Burtaine A (2015). “I learned to be okay with talking about sex and safety”: assessing the efficacy of a theatre-based HIV prevention approach for adolescents in North Carolina. Sex Educ;15(4):348-363.
Nunn KL, Wang YY, Harit D, Humphrys MS, Ma B, Cone R, Ravel J, and Lai SK (2015). Enhanced Trapping of HIV-1 by Human Cervicovaginal Mucus Is Associated with Lactobacillus crispatus-Dominant Microbiota. MBio. 6(5): e01084-15.
Onsomu EO, Abuya BA, Okech IN, Rosen DL, Duren-Winfield V, Simmons AC (2015). Association Between Domestic Violence and HIV Serostatus Among Married and Formerly Married Women in Kenya, Health Care Wom Int;36(2):205-28.
Powers KA and Miller WC (2015). Critical Review: Building on the HIV cascade: a complementary “HIV States and Transitions” framework for describing HIV diagnosis, care, and treatment at the population level. JAIDS;69(3):341-7.
Rahangdale L, De Paris K, Kashuba AD, Nelson JA, Cottrell M, Sykes C, Emerson C, Young SL, Stevens T, Patterson KB, Cohen MS (2015). Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women. J Acquir Immune Defic Syndr;68(4):420-4.
Rennie S, Perry B, Corneli A, Chilungo A, Umar E (2015). Perceptions of voluntary medical male
circumcision among circumcising and non-circumcising communities in Malawi. Glob Public
Rosenberg NE, Mtande TK, Saidi F, Stanley C, Jere E, Paile L, Kumwenda K, Mofolo I, Ng’ambi W, Miller WC, Hoffman I, Hosseinipour M (2015). Recruiting male partners for couple HIV testing and counselling in Malawi’s option B+ programme: an unblinded randomised controlled trial. Lancet HIV. 2015 Nov;2(11):e483-91.
Sin S-H, Kang SA, Kim Y, Eason A, Tan K, An H, and Dittmer DP (2015a). Kaposi’s sarcoma-associated herpesvirus latency locus compensates for interleukin-6 in initial B cell activation. J Virol;90(4):2150-2154.
Vielot N, Hudgens MG, Mugo N, Chitwa M, Kimani J, and Smith J (2015). The Role of Chlamydia trachomatis in High-Risk Human Papillomavirus Persistence Among Female Sex Workers in Nairobi, Kenya. Sex Transm Dis;42(6):305-11.
Yotebieng M, Norris A, Chalachala JL, Matumona Y, Ramadhani HO, Behets F (2015). Fertility desires, unmet need for family planning, and unwanted pregnancies among HIV-infected women in care in Kinshasa, DR Congo. Pan Afr Med J;20:235.
Denslow SA, Rositch AF, Firnhaber C, Ting J, and Smith JS (2014). Incidence and progression of
cervical lesions in women with HIV: a systematic global review. Int J STD AIDS;25(3):163-77.
Miller WC, Lesko CR, Powers KA (2014). The HIV care cascade: simple concept, complex realization. Sex Transm Dis;41(1):41-2.
Required Documents from new Developmental Awardees:
Acknowledgement of CFAR Developmental Financial Obligations
Human Subjects Study form (initially including Planned Enrollment Form and later, regular updates to the Cumulative Enrollment Form)
Final Developmental application, including budget and budget justification
.pdf copy of IRB approvals from any collaborating institutions as well as UNC
Photo of PI for CFAR website
Documentation of human subjects training for all study personnel
All informed consent forms